Holen Sie sich die Stockscreener-App
0.256
13.78%
0.031
Schlusskurs vom Vortag:
$0.225
Offen:
$0.234
24-Stunden-Volumen:
5.25M
Relative Volume:
1.58
Marktkapitalisierung:
$15.68M
Einnahmen:
$895.50K
Nettoeinkommen (Verlust:
$-26.30M
KGV:
-0.134
EPS:
-1.91
Netto-Cashflow:
$-23.84M
1W Leistung:
+14.29%
1M Leistung:
-1.16%
6M Leistung:
-55.22%
1J Leistung:
-76.94%
1-Tages-Spanne:
$0.2316
$0.2639
1-Wochen-Bereich:
$0.19
$0.2639
52-Wochen-Spanne:
$0.1852
$1.79
Mainz Biomed N V Stock (MYNZ) Company Profile
Firmenname
Mainz Biomed N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MYNZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
0.256 | 15.68M | 895.50K | -26.30M | -23.84M | -1.91 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | Eingeleitet | H.C. Wainwright | Buy |
Mainz Biomed N V Aktie (MYNZ) Neueste Nachrichten
Mainz Biomed (NASDAQ:MYNZ) Rating Lowered to “Neutral” at HC Wainwright - Defense World
What You Didn’t Know About Mainz Biomed N.V (NASDAQ: MYNZ) This Week - Stocks Register
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test - Nasdaq
Mainz Biomed and Thermo Fisher Scientific sign a collaboration agreement - Wiley
Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance - TipRanks
MAINZ BIOMED NV- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening Technology - Citybuzz
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening - Nasdaq
Mainz Biomed N.V. and Thermo Fisher Scientific Inc. Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - Marketscreener.com
Mainz Biomed Partners With Thermo Fisher To Advance Colorectal Cancer Screening - Contract Pharma
Mainz Biomed and Thermo Fisher Scientific Sign a - GlobeNewswire
Mainz Biomed Partners with Thermo Fisher for Next-Gen Cancer Screening Breakthrough | MYNZ Stock News - StockTitan
Is Now The Time To Buy Mainz Biomed N.V. (NASDAQ: MYNZ) Stock? - Stocks Register
Mainz Biomed’s half-yearly revenue increases 4% YoY - Medical Buyer
Mainz Biomed restructured operations, implemented cost reductions - Yahoo Finance
Mainz Biomed reports revenue growth and reduced losses By Investing.com - Investing.com South Africa
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed N : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Form 6 K - Marketscreener.com
Financial Metrics Unveiled: Mainz Biomed N.V. (MYNZ)’s Key Ratios in the Spotlight - The Dwinnex
Mainz Biomed N.V.: Navigating Market Fluctuations with a 5.69M Market Cap - The InvestChronicle
Stocks of Mainz Biomed N.V. (MYNZ) are poised to climb above their peers - SETE News
Evaluating MYNZ’s financial ratios for a profitable investment - US Post News
Investors’ Faith in Mainz Biomed N.V. (MYNZ) could reap rewards if they hold on for the long haul - US Post News
Mainz Biomed Secures Additional $1.5M Funding - Yahoo Finance
Mainz Biomed N.V. [MYNZ] Stock trading around $0.38 per share: What’s Next? - The DBT News
Mainz Biomed N : Material Definitive Agreement Form 6 K - Marketscreener.com
Views of Wall Street’s Leading Experts on Mainz Biomed N.V. - SETE News
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version - GlobeNewswire
Mainz Biomed N.V.: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Understanding MYNZ’s book value per share for better investment insights - US Post News
Market Watch: Mainz Biomed N.V. (MYNZ)’s Noteworthy Drop, Closing at 0.24 - The Dwinnex
Mainz Biomed Executes Convertible Note Agreement - TipRanks
Mainz Biomed plans FDA trial for cancer test in 2025 - Investing.com India
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - GlobeNewswire
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials - The Bakersfield Californian
Taking on analysts’ expectations and winning: Mainz Biomed N.V. (MYNZ) - SETE News
Mainz Biomed N.V. (MYNZ) Stock: A Year of Decreases and Increases - The InvestChronicle
Technical analysis of Mainz Biomed N.V. (MYNZ) stock chart patterns - US Post News
Market Highlights: Mainz Biomed N.V. (MYNZ) Ends on a High Note at 0.25 - The Dwinnex
What is Mainz Biomed N.V. (MYNZ) Stock Return on Shareholders’ Capital? - SETE News
Is Mainz Biomed N.V. (MYNZ) a good investment opportunity? - US Post News
Market Recap: Mainz Biomed N.V. (MYNZ)’s Negative Momentum, Closing at 0.24 - The Dwinnex
Mainz Biomed (NASDAQ:MYNZ) Stock Quotes, Forecast and News Summary - Benzinga
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador - GlobeNewswire
Financial Fitness Check: Examining Mainz Biomed N.V. (MYNZ)’s Key Ratios - The Dwinnex
It makes sense and dollars to buy Mainz Biomed N.V. (MYNZ) stock - SETE News
Mainz Biomed N.V. (MYNZ) deserves deeper analysis - US Post News
MYNZ Stock on the Rise: A Promising Investment - The InvestChronicle
Mainz Biomed to unveil breakthrough early cancer detection study results at DDW 2024 - MSN
Quarterly Snapshot: Quick and Current Ratios for Mainz Biomed N.V. (MYNZ) - The Dwinnex
Mainz Biomed stock plunges to 52-week low of $0.3 amid market challenges - Investing.com
Finanzdaten der Mainz Biomed N V-Aktie (MYNZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):